Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid-Reference-Cited by-同舟云学术

Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

Published:2017-04-27 Issue:7 Volume:96 Page:1069-1075
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Sanchez Ricardo,Ayala Rosa,Alonso Rafael Alberto,Martínez María Pilar,Ribera Jordi,García Olga,Sanchez-Pina José,Mercadal Santiago,Montesinos Pau,Martino Rodrigo,Barba Pere,González-Campos José,Barrios Manuel,Lavilla Esperanza,Gil Cristina,Bernal Teresa,Escoda Lourdes,Abella Eugenia,Amigo Ma Luz,Moreno Ma José,Bravo Pilar,Guàrdia Ramón,Hernández-Rivas Jesús-María,García-Guiñón Antoni,Piernas Sonia,Ribera José-María,Martínez-López Joaquín

Funder

Fundación Cris

Red tematica de investigación cooperativa en cancer

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-017-3002-1/fulltext.html

Reference21 articles.

1. Gaur S, Torabi AR, Corral J (2014) Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor. In Vivo 28:1149–1153

2. Del Principe MI, Maurillo L, Buccisano F et al (2014) Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis and therapy. Mediterr J Hematol Infect Dis 6:e2014075

3. O’Dwyer ME, Druker BJ (2000) STI571: an inhibitor of the BCR-ABL1 tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol 1:207–211

4. Shah NP, Tran C, Lee FY et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399–401

5. le Coutre P, Ottmann OG, Giles F et al (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL1 tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834–1839

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EXABS-164-ALL The Role of CNS Prophylaxis in the Era of Contemporary Therapy in Adults With Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-09

2. Diagnostic Significance of Cerebrospinal Fluid Flow Cytometry in Chinese Children with B Lineage Acute Lymphoblastic Leukemia;2023-08-11

3. Diagnosis and management of adult central nervous system leukemia;Blood Science;2023-05-30

4. Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study;Technology in Cancer Research & Treatment;2023-01

5. Neurological relapse of acute lymphoblastic leukemia mimicking COVID-19 associated Guillain-Barré Syndrome;Pediatric Hematology Oncology Journal;2022-09